Shares of LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) have received a consensus recommendation of "Buy" from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $12.00.
Several brokerages have recently commented on LFMD. HC Wainwright restated a "buy" rating and set a $12.00 price target on shares of LifeMD in a research note on Monday, November 11th. B. Riley started coverage on shares of LifeMD in a research report on Friday, August 23rd. They set a "buy" rating and a $11.00 target price on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $15.00 target price on shares of LifeMD in a report on Friday, September 20th.
Get Our Latest Stock Report on LifeMD
Shares of LifeMD stock opened at $6.34 on Wednesday. The stock has a 50-day simple moving average of $5.06 and a 200-day simple moving average of $6.08. LifeMD has a 52-week low of $3.99 and a 52-week high of $12.88. The firm has a market cap of $274.59 million, a price-to-earnings ratio of -9.91 and a beta of 1.23. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.83 and a quick ratio of 0.78.
A number of hedge funds have recently bought and sold shares of LFMD. State Street Corp grew its holdings in LifeMD by 20.0% in the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company's stock valued at $6,055,000 after buying an additional 192,861 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of LifeMD by 12.5% in the first quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company's stock worth $11,875,000 after acquiring an additional 128,701 shares during the last quarter. Royce & Associates LP increased its position in LifeMD by 14.6% during the third quarter. Royce & Associates LP now owns 901,041 shares of the company's stock worth $4,721,000 after acquiring an additional 114,710 shares during the period. Los Angeles Capital Management LLC raised its stake in LifeMD by 852.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company's stock valued at $637,000 after purchasing an additional 108,822 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in LifeMD by 63.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company's stock valued at $1,609,000 after purchasing an additional 91,183 shares during the period. 35.52% of the stock is currently owned by institutional investors.
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider LifeMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.
While LifeMD currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.